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This article expands on crystal structure data for human H-RAS
with mutations at position Y137, brieﬂy described in a paper on
the effects of phosphorylation of Y137 by ABL kinases (Tyrosine
phosphorylation of RAS by ABL allosterically enhances effector
binding, published in the FASEB Journal [1]). The crystal structures
of the Y137E mutant (phosphorylation mimic) and of the Y137F
mutant (without the hydroxyl group where phosphorylation
occurs) were deposited in the Protein Data Bank with PDB codes
4XVQ (H-RASY137E) and 4XVR (H-RASY137F). This article includes
details for expression and puriﬁcation of RAS and its mutants with
no afﬁnity tags, in vitro exchange of guanine nucleotides, protein
crystallization, X-ray data collection and structure reﬁnement.
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
ore speciﬁc sub-
ject areaStructural biologyvier Inc. This is an open access article under the CC BY license
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C.W. Johnson et al. / Data in Brief 6 (2016) 423–427424ype of data Molecular models obtained by protein X-ray crystallography
ow data was
acquiredX-day diffraction data on the protein crystals were obtained using a HighFlux
HomeLab consisting of a Rigaku MicroMax-007HF, a second generation
microfocus rotating anode generator with a 70 μm diameter focal spot. The
X-ray generator is mounted on a R-Axis IVþþ image plate detector with
VariMaxHR optics.ata format X-ray data processed with HKL3000
xperimental
factorsX-ray data were collected at a temperature of 100 K and with a crystal to
detector distance of 120 mm.xperimental
featuresProtein puriﬁcation did not involve afﬁnity tags. The reservoir solution in the
crystallization plates contained a small amount of the buffer solution present
in the crystallization drop. Crystals were cryo-protected with crystallization
solution containing 30% glycerol prior to freezing in liquid nitrogen.ata source
locationBoston, MA United Statesata accessibility Data were deposited in the Protein Data Bank (PDB). The accession codes are
PDB: 4XVQ and PDB: 4XVR.Value of the data
 Structural data on RAS are essential for understanding its function.
 The methods we used to study RAS can in general elucidate the links between mutations at an
allosteric site and catalysis at the active site of proteins.
 The protocols presented here can be used in general to obtain the structure of any RAS mutant.1. Data, experimental design, materials and methods
The experimental protocols presented here focus on data collection for the structural analysis of RAS
proteins and their mutants. RAS exists in three major isoforms, H-, K- and N-RAS, which together are found
mutated in about 20% of all human cancers. While the most common mutation sites are at residues G12,
G13 and Q61, mutants at other sites are also found in human tumors [2]. The type of data presented here is
important for studying oncogenic mutants, but they are also essential for making mutants that test the
relevance of particular structural features to the function of RAS, as was the case for the allosteric switch
mutants that we recently published [1]. The present article provides details on how to express and purify
any of the RAS isoforms and their mutants with a truncated C-terminal hypervariable region.
Mutagenesis, protein puriﬁcation, and crystallization were done using the G-domain (residues 1–
166) of wild type H-RAS (EC 3.6.5.2) inserted into the pET21 vector system. Primer design for
mutagenesis was done according to the QuikChanges site-directed mutagenesis protocol. The Y137E
mutant was made using parameters recommended by the QuikChanges manual. The Y137F mutant
was made using a previously published two-step mutagenesis procedure [3]. Targeted mutagenesis
was conﬁrmed by third-party sequencing (Euroﬁns MWG-Operon). Plasmids containing the cDNA for
H-RASY137E and H-RASY137F were used to transform Escherichia coli, strain BL21, in order to express
and purify the mutant proteins.
For protein expression, 200 mL of Luria Broth (LB) containing ampicillin (50 mg/mL) was inocu-
lated with transformed BL21 cells and grown overnight at 37 °C. On the following day, six Fernbach
ﬂasks, each with 1 L of LB containing ampicillin, were inoculated with 25 mL of the overnight culture.
Cell growth was monitored until the optical density (O.D.) reached 0.6 (80–120 min), as measured by
a SmartSpec™ Plus spectrophotmeter. Protein expression was then induced by adding dry IPTG to a
ﬁnal concentration of 0.5 mM in each liter of growing E. coli. The temperature was reduced to 32 °C,
and protein expression was allowed to continue for six hours. Cultures were shaken at 225 rpm
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centrifugation at 7000 rpm for 20 min at 4 °C and the cell pellet stored at 80 °C.
For protein puriﬁcation, cells were solubilized (200–300 mg of cells/mL) in buffer A (20 mM Tris,
pH 8.0, 5 mM MgCl2, 50 mM NaCl, 5% glycerol, 20 mM GDP, 1 mM DTT) containing benzamidine
(40.0 mM), leupeptin (0.17 mM), and antipain (0.12 mM). H-RASY137F suspension also contained pefabloc
(8.0 mM). Cells were lysed by sonication (60 Sonic Dismembrator from Fisher Scientiﬁc) for 30 s at
18 W, followed by 30 s of rest, on ice in a metal cup. Five rounds of sonication were performed. The
sonicated lysate was clariﬁed by centrifugation at 14,000 rpm for 20 min at 4 °C. Polyethyleneimine
(PEI, 0.02% w/v) was then used to precipitate contaminating nucleic acids and proteins [4] in the
lysate supernatant. Precipitation of unwanted macromolecules with PEI was done on ice, while the
lysate solution was stirred gently for 30 min. After precipitation, clariﬁcation of lysate was again
performed by centrifugation at 14,000 rpm for 20 min at 4 °C. Just prior to chromatography, the
protein solution was passed through a 0.45 mm pore membrane using syringe ﬁltration to remove
remaining cell debris and large protein aggregates.
Chromatography for puriﬁcation of H-RASY137E and H-RASY137F was done using a ÄKTA FPLC system
(GE Healthcare) at 4 °C. The ﬁrst step was anion exchange (HiPrep™ 16/10 QFF column, 20 mL column
volume (cv), GE Healthcare). Binding of mutant H-RAS to a QFF column was done in buffer A without
protease inhibitors and at a ﬂow rate of 4 mL/min. After protein binding, the column was washed with
two column volumes of buffer A. Protein elution was performed using a 200 mL gradient of 0–40% buffer
B (20 mM Tris, pH 8.0, 5 mM MgCl2, 1 M NaCl, 5% glycerol, 20 mM GDP, 1 mM DTT) at 4 mL/min. Fig. 1a
and b shows SDS-PAGE of sample fractions coming off the QFF column as the gradient increases. The two
mutants are very similar in terms of their migration in this column. H-RasY137E and H-RasY137F eluted off
the QFF column at around 15–25% buffer B, which is common for RAS and its mutants. Only the fractionsba c
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Fig. 1. 15% SDS-PAGE gels of generalized puriﬁcation of H-Ras Y137F and E. Puriﬁcations of Y137F and Y137E are very similar.
Lanes represent fractions collected from anion exchange chromatography and gel ﬁltration. Fractions from anion exchange are
described in terms of percentage of buffer B and column volume (cv); fractions for gel ﬁltration are in terms of cv only. Panel
(a) shows results from QFF of H-Ras Y137E. Lanes for panel (a) are: (1) MW ladder, (2) 7% B and 7.7 cv, (3) 11% B and 9.1 cv,
(4) 16% B and 10 cv, (5) 18% B and 11 cv, and (6) 23% B and 13 cv. Panel (b) shows results from QFF of H-Ras Y137F. Lanes for
panel (b) are: (1) 8.5% B and 8.5 cv, (2) 13% B and 9.9 cv, (3) 17% B and 11 cv, and (4) 23% B and 13 cv. Panel (c) shows results of
gel ﬁltration of H-Ras Y137F. Lanes for panel (c) are: (1) MW ladder, (2) 0.51 cv, (3) 0.53 cv, (4) 0.54 cv, (5) 0.55 cv, and
(6) 0.57 cv. Panel (d) shows results for QHP of H-Ras Y137E. Lanes for panel (d) are: (1) MW ladder, (2) 14.5% B and 20.3 cv,
(3) 14.8% B and 29.8 cv, (4) 15.3% B and 30.6 cv, (5) 15.8% B and 31.4 cv, (6) 16.2% B and 32.2 cv, (7) 16.7% B and 33.0 cv, and
(8) 16.8% B and 33.8 cv. The red arrow depicts the H-Ras mutant (18.8 kDa), and the markers for the ladder are shown on the
left of gels (a), (c), and (d).
Fig. 2. SDS-PAGE showing purity of H-RASY137F and H-RASY137E. Left side of 15% SDS-PAGE shows H-RASY137E and right side
shows H-RASY137F. The 10 lanes on the gel represent the following: MW ladder (lanes 1 and 6), H-RASY137E bound to GDP (lane
2), H-RASY137E bound to GppNHp (lane 3), 5-fold dilution of H-RASY137E bound to GDP (lane 4), 5-fold dilution of H-RASY137E
bound to GppNHp (lane 5), H-RASY137E bound to GDP (ladder 7), H-RASY137E bound to GppNHp (lane 8), 5-fold dilution of
H-RASY137E bound to GDP (lane 9), and 5-fold dilution of H-RASY137E bound to GppNHp (lane 10). The red arrow depicts the
H-Ras mutant (18.8 kDa), and the markers for the MW ladder are shown on the left.
Fig. 3. Crystals of wild type H-RAS with symmetry of space group P3221.
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chromatography step was size exclusion (HiPrep™ 26/60 Sephacryl S-100 or S-200 column, 320 mL cv,
GE Healthcare) using Buffer A at a rate of 1 mL/min. Fig. 1c shows an example of the gel ﬁltration fractions
containing H-RASY137F. This mutant was pure enough at this stage to be used for crystallization. Gel
ﬁltration was also performed for H-RASY137E mutant (results are not shown). Some mutants, such as H-
RASY137E, require an additional puriﬁcation step. For this we use a higher resolution, anion exchange
chromatography column (HiTrap™ QHP column, 5 mL cv, GE Healthcare). The Y137E protein was bound
to the QHP column using buffer A at 4 mL/min. After protein binding, the column was washed with
4 column volumes of buffer A. Protein was eluted from the QHP column using 0–25% buffer B over
200 mL, at a rate of 4 mL/min. Fig. 1d shows the Y137E mutant RAS protein eluted from the QHP column,
pure enough to be used for crystallization.
In general, RAS proteins are puriﬁed bound to GDP. This was the case for both H-RASY137E and H-
RASY137F. However, our interest is in the GTP-bound active state. Since GTP is hydrolyzed to GDP in the
experimental time frame for structure determination we loaded RAS with the GTP analog guanylyl-
imidodiphosphate (GppNHp). Nucleotide exchange of GDP for GppNHp was performed by ﬁrst trans-
ferring the protein into Nucleotide Exchange (NE) buffer (32 mM Tris pH 8.0, 200 mM ammonium sulfate,
10 mM DTT, and 0.15% N-octylglucopyranoside) using Illustra™ Sephadex™ DNA grade gravity columns
(GE Healthcare), following the manufacture's instructions. Once exchanged into NE buffer, 1 mg of
GppNHp, and 50 U of alkaline phosphatase linked to agarose beads (Sigma-Aldrichs) were added per
10 mg of protein. Protein was then gently rotated for 30–60 min at 37 °C. After nucleotide exchange, a
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20 mM MgCl2. After 5 min at room temperature, the protein solution was exchanged into a stabilization
buffer (20 mM HEPES, pH 7.5, 50 mM NaCl, 20 mM MgCl2, 1 or 10 mM DTT). The protein was then
concentrated, ﬂash frozen, and stored at 80 °C until it was used for crystallization. Fig. 2 shows SDS-
PAGE for the puriﬁed H-RASY137E and RASY137F proteins prior to crystallization.
All reagents and materials for crystallization were purchased from Hampton Research, Inc. Crystals
were grown in 24-well plates with reservoir volumes ranging from 425 mL to 625 mL. H-RASY137E was
crystallized in hanging drops containing 2 mL protein at a concentration of 12.4 mg/mL in stabilization
buffer and 2 mL of reservoir solution consisting of 152 mM Ca(OAc)2, 24.8% PEG 3350, and 4.8% sta-
bilization buffer at pH 7.5. For H-RASY137F crystallization, the protein was at a concentration of
20.7 mg/mL and the reservoir contained 139 mM Ca(OAc)2, 22.6% PEG 3350, and 13% stabilization
buffer at pH 7.5. Both proteins crystallized with symmetry of space group P3221. Fig. 3 shows crystals
of wild type H-RAS in this crystal form. The mutant crystals look similar. Data for H-RASY137E and H-
RASY137F were collected using a Rigaku X-ray generator at a temperature of 100 K with X-ray wave-
length of 1.54 Å. Data were processed with HKL2000 [5]. The coordinates with PDB code 1CTQ were
used as a phasing model for molecular replacement, followed by reﬁnement using the PHENIX suite
of programs [6] and model building using COOT [7]. Several rounds of reﬁnement were done, starting
with the protein model, followed by subsequent addition of the GppNHp molecule and crystal-
lographic water molecules. The table of data collection and structure reﬁnement statistics is found in
the original publication, as are ﬁgures showing the structures of the mutant Ras proteins [1].Conﬂicts of interest
NoneAcknowledgments
This work was supported by a grant from the U.S. National Science Foundation: MCB-1244203.Appendix A. Suplementary information
Supplementary data associated with this article can be found in the online version at: http://dx.
doi.org/10.1016/j.dib.2015.12.007.References
[1] P.Y. Ting, C.W. Johnson, C. Fang, X. Cao, T.G. Graeber, C. Mattos, J. Colicelli, Tyrosine phosphorylation of RAS by ABL allos-
terically enhances effector binding, FASEB J. (2015) 15–271510.
[2] S.A. Forbes, N. Bindal, S. Bamford, C. Cole, C.Y. Kok, D. Beare, M. Jia, R. Shepherd, K. Leung, A. Menzies, J.W. Teague, P.
J. Campbell, M.R. Stratton, P.A. Futreal, COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in
Cancer, Nucleic Acids Res. 39 (2011) D945–D950.
[3] W. Wang, B.A. Malcolm, Two-stage polymerase chain reaction protocol allowing introduction of multiple mutations,
deletions, and insertions, using quick change (™) site-directed mutagenesis, in: J. Braman (Ed.), in vitro Mutagenesis
Protocols, 2nd ed.,Humana Press Inc., Totowa, NJ, 2001, pp. 37–43.
[4] R.R. Burgess, Protein precipitation techniques, in: R.R. Burgess, M.P. Deutscher (Eds.), Methods in Enzymology, 463, Elsevier,
San Diego, 2009, pp. 331–342.
[5] Z. Otwinowski, W. Minor, Processing of X-ray diffraction in oscillation mode, in: Method in Enzymology, vol. 276, Elsevier,
San Diego, 1997, pp. 307–326.
[6] P.D. Adams, P.V. Afonine, G. Bunkoczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.W. Hung, G.J. Kapral, R.W. Grosse-
Kunstleve, A.J. McCoy, N.W. Moriarty, R. Oeffner, R.J. Read, D.C. Richardson, J.S. Richardson, T.C. Terwilliger, P.H. Zwart,
PHENIX: a comprehensive Python-based system for macromolecular structure solution, Acta Crystallogr. D. 66 (2010)
213–221.
[7] P. Emsley, K. Cowtan, COOT: model building tools for molecular graphics, Acta Crystallogr. D. 60 (2004) 2126–2132.
